We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » To End Clinical Hold, Repros Must Revise Proposed Trial
To End Clinical Hold, Repros Must Revise Proposed Trial
May 12, 2010
Repros Therapeutics must change its proposed dose-finding safety trial of Proellex from a parallel design to an escalating dose design for the FDA to remove a clinical hold on the uterine fibroids and endometriosis drug.